Vestal Point Capital LP Buys 265,000 Shares of Alto Neuroscience, Inc. (NYSE:ANRO)

Vestal Point Capital LP grew its stake in Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) by 40.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 915,000 shares of the company's stock after purchasing an additional 265,000 shares during the quarter. Vestal Point Capital LP owned approximately 3.39% of Alto Neuroscience worth $3,870,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of ANRO. Barclays PLC grew its stake in shares of Alto Neuroscience by 872.7% in the third quarter. Barclays PLC now owns 29,599 shares of the company's stock valued at $339,000 after acquiring an additional 26,556 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Alto Neuroscience by 543.4% in the third quarter. JPMorgan Chase & Co. now owns 24,315 shares of the company's stock valued at $278,000 after acquiring an additional 20,536 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Alto Neuroscience by 24.4% in the fourth quarter. Rhumbline Advisers now owns 25,556 shares of the company's stock valued at $108,000 after acquiring an additional 5,008 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Alto Neuroscience by 15.0% in the fourth quarter. Bank of New York Mellon Corp now owns 52,271 shares of the company's stock valued at $221,000 after acquiring an additional 6,812 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Alto Neuroscience in the fourth quarter valued at about $74,000.

Analysts Set New Price Targets

Several equities analysts recently commented on ANRO shares. William Blair restated an "outperform" rating on shares of Alto Neuroscience in a research note on Friday, March 21st. Wedbush restated a "neutral" rating and issued a $4.00 price target on shares of Alto Neuroscience in a research note on Thursday, May 15th. Finally, HC Wainwright started coverage on shares of Alto Neuroscience in a research note on Monday, April 7th. They issued a "buy" rating and a $10.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Alto Neuroscience has a consensus rating of "Moderate Buy" and an average price target of $15.40.

Alto Neuroscience Price Performance

Alto Neuroscience stock traded up $0.12 during trading hours on Friday, reaching $3.05. 276,114 shares of the stock were exchanged, compared to its average volume of 385,196. The company has a market cap of $82.68 million, a P/E ratio of -1.31 and a beta of 1.87. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05. Alto Neuroscience, Inc. has a twelve month low of $1.60 and a twelve month high of $17.55. The stock has a 50 day moving average of $2.35 and a two-hundred day moving average of $3.40.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.06. Equities analysts expect that Alto Neuroscience, Inc. will post -2.54 EPS for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.